ATE536178T1 - Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis - Google Patents

Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis

Info

Publication number
ATE536178T1
ATE536178T1 AT04810055T AT04810055T ATE536178T1 AT E536178 T1 ATE536178 T1 AT E536178T1 AT 04810055 T AT04810055 T AT 04810055T AT 04810055 T AT04810055 T AT 04810055T AT E536178 T1 ATE536178 T1 AT E536178T1
Authority
AT
Austria
Prior art keywords
methionine
mucositis
treatment
prevention
therapeutic use
Prior art date
Application number
AT04810055T
Other languages
English (en)
Inventor
Kathleen C M Campbell
Original Assignee
Univ Southern Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern Illinois filed Critical Univ Southern Illinois
Application granted granted Critical
Publication of ATE536178T1 publication Critical patent/ATE536178T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
AT04810055T 2003-10-27 2004-10-27 Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis ATE536178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/694,436 US20050090551A1 (en) 2003-10-27 2003-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis
PCT/US2004/035626 WO2005039554A2 (en) 2003-10-27 2004-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis

Publications (1)

Publication Number Publication Date
ATE536178T1 true ATE536178T1 (de) 2011-12-15

Family

ID=34522601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810055T ATE536178T1 (de) 2003-10-27 2004-10-27 Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis

Country Status (8)

Country Link
US (1) US20050090551A1 (de)
EP (1) EP1677775B1 (de)
JP (1) JP4884974B2 (de)
AT (1) ATE536178T1 (de)
AU (1) AU2004283756B2 (de)
CA (1) CA2543870C (de)
ES (1) ES2376102T3 (de)
WO (1) WO2005039554A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071230B2 (en) * 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
JP2009531461A (ja) * 2006-03-28 2009-09-03 ノバス インターナショナル インク 発毛促進用組成物
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
KR20180041269A (ko) 2008-01-22 2018-04-23 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
WO2009111057A2 (en) 2008-03-07 2009-09-11 Scidose Llc Fulvestrant formulations
US20120148509A1 (en) * 2009-09-14 2012-06-14 Shiseido Company, Ltd. Composition for alleviating ultraviolet irradiation-induced damage
KR20120044993A (ko) * 2009-09-30 2012-05-08 가부시키가이샤 시세이도 자외선 장해 경감 경구 조성물
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
JP5578997B2 (ja) * 2010-09-16 2014-08-27 国立大学法人 大分大学 がん化学療法誘発脱毛に対する抗脱毛用組成物
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CN112839663A (zh) * 2018-08-14 2021-05-25 托斯克公司 降低氟尿嘧啶诱发的毒性的方法和组合物
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
CN114051974B (zh) * 2021-11-10 2023-01-17 广西医科大学 一种肝癌模型及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652290A (en) * 1970-08-10 1972-03-28 Merck & Co Inc Beverages containing stabilized vitamin c
US3962429A (en) * 1973-08-01 1976-06-08 Chugai Seiyaku Kabushiki Kaisha Method for reducing side effects of aminoglycoside antibiotics and composition therefor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5122369A (en) * 1990-03-30 1992-06-16 Harmony Health Products, Inc. Nutrient composition for preventing hair loss
AU703079B2 (en) * 1994-07-01 1999-03-11 Procter & Gamble Company, The Desquamation compositions
JPH08190187A (ja) * 1995-01-11 1996-07-23 Canon Inc 情報記録装置
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
ATE323475T1 (de) * 1996-10-03 2006-05-15 Univ Southern Illinois D-methionin zur reduzierung der toxizität von platin-enthaltenden antitumor verbindungen
EP1917966B1 (de) * 1998-02-13 2010-01-20 Nutramax Laboratories, Inc. Mittel und Verfahren zum Schutz, zur Behandlung und Reparatur von Bindegewebe
JP4674021B2 (ja) * 1999-07-13 2011-04-20 ビオヴィトルム・アクチボラゲット（プブリクト） 安定第ｖｉｉｉ因子組成物
AU2002249863A1 (en) * 2000-10-24 2002-08-12 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioether or a hydrophilic 6-hydroxy chroman
DK1343492T3 (da) * 2000-11-22 2006-03-06 Rxkinetix Inc Behandling af mucositis
KR20030088453A (ko) * 2001-03-09 2003-11-19 소시에떼 데 프로듀이 네슬레 소시에떼아노님 연령 관련 생리학적 부전 개선 및 수명 연장을 위한 조성물
EP1461033B1 (de) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Verfahren und zusammensetzungen zur linderung von unerwünschten wirkungen einer chemotherapie
WO2004080429A2 (en) * 2003-03-13 2004-09-23 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties

Also Published As

Publication number Publication date
AU2004283756A2 (en) 2005-05-06
EP1677775B1 (de) 2011-12-07
EP1677775A2 (de) 2006-07-12
JP2007509955A (ja) 2007-04-19
JP4884974B2 (ja) 2012-02-29
CA2543870C (en) 2013-03-12
AU2004283756A1 (en) 2005-05-06
AU2004283756B2 (en) 2010-07-29
ES2376102T3 (es) 2012-03-09
US20050090551A1 (en) 2005-04-28
CA2543870A1 (en) 2005-05-06
WO2005039554A3 (en) 2005-12-15
WO2005039554A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
NO20000688L (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
ECSP055970A (es) Uso de palonosetron para el tratamiento de nausea y vomito post operatorio
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
BRPI0507048A (pt) uso de baixa dosagem de eritropoetina para estimular células precursoras endoteliais, regenerar órgãos e retardar a progressão de danos em órgão alvo
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
JP2005508896A5 (de)
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20064753L (no) Kombinasjonsterapi
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
EA201270298A1 (ru) Способ лечения злокачественной опухоли
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors